Liver Failure/Cirrhosis/Portal Hypertension

You have full text access to this OnlineOpen article

L-ornithine phenylacetate attenuates increased arterial and extracellular brain ammonia and prevents intracranial hypertension in pigs with acute liver failure†‡

  1. Lars Marius Ytrebø1,§,*,
  2. Rune Gangsøy Kristiansen1,
  3. Hanne Mæhre2,
  4. Ole Martin Fuskevåg3,
  5. Trine Kalstad4,
  6. Arthur Revhaug4,
  7. María Jover Cobos5,
  8. Rajiv Jalan6,¶,*,
  9. Christopher F. Rose7,*

Article first published online: 18 FEB 2009

DOI: 10.1002/hep.22917

Issue

Hepatology

Hepatology

Volume 50, Issue 1, pages 165–174, July 2009

Additional Information

How to Cite

Ytrebø, L. M., Kristiansen, R. G., Mæhre, H., Fuskevåg, O. M., Kalstad, T., Revhaug, A., Cobos, M. J., Jalan, R. and Rose, C. F. (2009), L-ornithine phenylacetate attenuates increased arterial and extracellular brain ammonia and prevents intracranial hypertension in pigs with acute liver failure. Hepatology, 50: 165–174. doi: 10.1002/hep.22917

Author Information

  1. 1

    Department of Anesthesiology, University Hospital of North Norway and University of Tromsø, Norway

  2. 2

    Institute of Marine Biotechnology, University of Tromsø, Norway

  3. 3

    Department of Clinical Pharmacology, University Hospital of North Norway and University of Tromsø, Norway

  4. 4

    Department of Digestive Surgery, University Hospital of North Norway and University of Tromsø, Norway

  5. 5

    Unit for Clinical Management of Digestive Diseases-CIBERehd, Hospital Universitario de Valme, Seville, Spain

  6. 6

    Liver Failure Group, Institute of Hepatology, University College London Medical School, UK

  7. 7

    Neuroscience Research Unit, Hôpital Saint-Luc (CRCHUM), Université de Montréal, Québec, Canada

  1. §

    fax: +47 776 26192

  2. fax: +44 207 3800405

*Department of Anesthesiology, University Hospital of North Norway and University of Tromsø, N-9038 Tromsø, Norway

  1. †

    Potential conflict of interest: University College London has filed for patents surrounding the use of L-Ornithine and Phenylacetate/Phenylbutyrate for the treatment of hepatic encephalopathy, which has been licensed to Ocera Therapeutics.

  2. ‡

    See Editorial on Page 3

Publication History

  1. Issue published online: 23 JUN 2009
  2. Article first published online: 18 FEB 2009
  3. Accepted manuscript online: 18 FEB 2009 12:00AM EST
  4. Manuscript Accepted: 9 FEB 2009
  5. Manuscript Received: 6 MAY 2008

Funded by

  • Norwegian Research Council
  • Helse Nord
  • Fonds de Recherche en Santé du Quebec (FRSQ, Canada)
  • University College London Business

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (900K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Liliane Mpabanzi, Rajiv Jalan, Neurological complications of acute liver failure: Pathophysiological basis of current management and emerging therapies, Neurochemistry International, 2012, 60, 7, 736

    CrossRef

  2. 2
    Marc Oria, Jordi Romero-Giménez, José Antonio Arranz, Encarnació Riudor, Núria Raguer, Juan Córdoba, Ornithine phenylacetate prevents disturbances of motor-evoked potentials induced by intestinal blood in rats with portacaval anastomosis, Journal of Hepatology, 2012, 56, 1, 109

    CrossRef

  3. 3
    William M. Lee, Recent developments in acute liver failure, Best Practice & Research Clinical Gastroenterology, 2012, 26, 1, 3

    CrossRef

  4. 4
    Gavin Wright, Balasubramaniyan Vairappan, Vanessa Stadlbauer, Rajeshwar P. Mookerjee, Nathan A. Davies, Rajiv Jalan, Reduction in hyperammonaemia by ornithine phenylacetate prevents lipopolysaccharide-induced brain edema and coma in cirrhotic rats, Liver International, 2012, 32, 3
    Direct Link:
  5. 5
    Bruno Ozanne, John Nelson, Jocelyne Cousineau, Marie Lambert, Véronique Phan, Grant Mitchell, Fernando Alvarez, Thierry Ducruet, Philippe Jouvet, Threshold for toxicity from hyperammonemia in critically ill children, Journal of Hepatology, 2012, 56, 1, 123

    CrossRef

  6. 6
    Peter Nissen Bjerring, Martin Eefsen, Fin Stolze Larsen, William Bernal, Julia Wendon, Hypermagnesemia does not prevent intracranial hypertension and aggravates cerebral hyperperfusion in a rat model of acute hyperammonemia, Hepatology, 2011, 53, 6
    Direct Link:
  7. 7
    Gavin Wright, Lorette Noiret, Steven W. M. Olde Damink, Rajiv Jalan, Interorgan ammonia metabolism in liver failure: the basis of current and future therapies, Liver International, 2011, 31, 2
    Direct Link:
  8. 8
    Tony Kelly, Christine R. Rose, Ammonium influx pathways into astrocytes and neurones of hippocampal slices, Journal of Neurochemistry, 2010, 115, 5
    Direct Link:
  9. 9
    Kerstin Zwirner, Christian Thiel, Karolin Thiel, Matthias H. Morgalla, Alfred Königsrainer, Martin Schenk, Extracellular brain ammonia levels in association with arterial ammonia, intracranial pressure and the use of albumin dialysis devices in pigs with acute liver failure, Metabolic Brain Disease, 2010, 25, 4, 407

    CrossRef

  10. You have free access to this content10
    Hisataka Moriwaki, Makoto Shiraki, Junpei Iwasa, Yoichi Terakura, Hepatic encephalopathy as a complication of liver cirrhosis: An Asian perspective, Journal of Gastroenterology and Hepatology, 2010, 25, 5
    Direct Link:
  11. 11
    B. Dunkel, Intestinal hyperammonaemia in horses, Equine Veterinary Education, 2010, 22, 7
    Direct Link:
  12. 12
    Fin Stolze Larsen, Julia Wendon, Alternative pathway therapy for hyperammonemia in liver failure, Hepatology, 2009, 50, 1
    Direct Link:
  13. 13
    Rajiv Jalan, William M. Lee, Treatment of Hyperammonemia in Liver Failure: A Tale of Two Enzymes, Gastroenterology, 2009, 136, 7, 2048

    CrossRef

View Full Article with Supporting Information (HTML) Get PDF (900K)